Compare SRRK & VISN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | VISN |
|---|---|---|
| Founded | 2012 | 1976 |
| Country | United States | United States |
| Employees | 289 | 4500 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 2018 | N/A |
| Metric | SRRK | VISN |
|---|---|---|
| Price | $40.03 | $17.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $55.10 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 4.1M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.06 |
| Revenue Next Year | $449.79 | $5.32 |
| P/E Ratio | ★ N/A | $5.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.71 | $16.50 |
| 52 Week High | $49.82 | $19.91 |
| Indicator | SRRK | VISN |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 45.03 |
| Support Level | $29.32 | $17.16 |
| Resistance Level | $42.54 | $19.51 |
| Average True Range (ATR) | 2.24 | 0.80 |
| MACD | -0.62 | -0.01 |
| Stochastic Oscillator | 1.77 | 58.33 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.